MDM2: A novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling

American Journal of Pathology

Volumn 169, Issue 2, 2006, Pages 362-371

  Nakamura, Yasuhiro ^a   Suzuki, Saya ^a   Suzuki, Takashi ^a   Ono, Katsuhiko ^a   Miura, Ikumi ^a   Satoh, Fumitoshi ^a   Moriya, Takuya ^a   Saito, Haruo ^b   Yamada, Shogo ^a   Ito, Sadayoshi ^a   Sasano, Hironobu ^a,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SENDAI CITY MEDICAL CENTER   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPLERENONE; GENE PRODUCT; HORMONE RECEPTOR BLOCKING AGENT; MINERALOCORTICOID RECEPTOR; PROTEIN MDM2; SMALL INTERFERING RNA;

ADRENAL CORTEX TUMOR; APOPTOSIS; ARTERY RESISTANCE; ARTICLE; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE INDUCTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERALDOSTERONISM; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MDM2 GENE; MICROARRAY ANALYSIS; MINERALOCORTICOID RESPONSIVE GENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE;

EID: 33746613199     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051351     Document Type: Article

References (38)

1. Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005, 96:643-650
2. Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994, 63:451-486
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321
4. Xiao F, Puddefoot JR, Barker S, Vinson GP: Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004, 44:340-345
5. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M: Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005, 97:434-442
6. Takeda Y: Role of cardiovascular aldosterone in hypertension. Curr Med Chem Cardiovasc Hematol Agents 2005, 3:261-266
7. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti-Rosei E: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996, 28:785-790
8. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, Yoshizumi M: Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005, 46:1046-1052
9. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE: Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005, 5:709-718
10. Iseki A, Kambe F, Okumura K, Niwata S, Yamamoto R, Hayakawa T, Seo H: Pyrrolidine dithiocarbamate inhibits TNF-alpha-dependent activation of NF-kappaB by increasing intracellular copper level in human aortic smooth muscle cells. Biochem Biophys Res Commun 2000, 276:88-92
11. Nakamura Y, Igarashi K, Suzuki T, Kanno J, Inoue T, Tazawa C, Saruta M, Ando T, Moriyama N, Furukawa T, Ono M, Moriya T, Ito K, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H: E4F1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis. Am J Pathol 2004, 165:2019-2031
12. Arcuri F, Sestini S, Ricci C, Runci Y, Carducci A, Paulesu L, Cintorino M: Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 2000, 72:239-247
13. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP: Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175-182
14. Krozowski Z, MaGuire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK: Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 1995, 80:2203-2209
15. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374
16. Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, Roth JA, Taya Y, Tanaka N, Fujiwara T: Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Mol Cancer Ther 2004, 3:93-100
17. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003, 9:931-946
18. Dilla T, Velasco JA, Medina DL, Gonzalez-Palacios JF, Santisteban P: The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Endocrinology 2000, 141:420-429
19. Tan Z, Qu W, Tu W, Liu W, Baudry M, Schreiber SS: p53 accumulation due to down-regulation of ubiquitin: relevance for neuronal apoptosis. Cell Death Differ 2000, 7:675-681
20. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H: Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol 2004, 219:17-26
21. Ihling C, Haendeler J, Menzel G, Hess RD, Fraedrich G, Schaefer HE, Zeiher AM: Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol 1998, 185:303-312
22. Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A: Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998, 124:1128-1133
23. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275
24. Farman N, Bocchi B: Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000, 57:1364-1369
25. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C: Localisation of 11 beta-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989
26. Fundel JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585
27. Kayes-Wandover KM, White PC: Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000, 85:2519-2525
28. Amano T, Matsubara T, Izawa H, Torigoe M, Yoshida T, Hamaguchi Y, Ishii H, Miura M, Hayashi Y, Ogawa Y, Murohara T: Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006, 97:785-788
29. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ: Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993, 8:2353-2260
30. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ: The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993, 90:11623-11627
31. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992, 70:523-526
32. Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995, 96:2260-2268
33. Bennett MR, Littlewood TD, Schwartz SM, Weissberg PL: Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ Res 1997, 81:591-599
34. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698
35. Phelps M, Phillips A, Darley M, Blaydes JP: MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 2005, 280:16651-16658
36. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M, McCormick F: Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103:321-330
37. Xu C, Lee S, Singh TM, Sho E, Li X, Sho M, Masuda H, Zarins CK: Molecular mechanisms of aortic wall remodeling in response to hypertension. J Vasc Surg 2001, 33:570-578
38. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JM, Danser AH: Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol 2005, 145:664-671